21 CFR Part 4 · Regulation of Combination Products

§ 4.103 What information must you share with other constituent part applicants for the combination product?

Subpart B - Postmarketing Safety Reporting for Combination Products Official text on eCFR Amendment history

(a) When you receive information regarding an event that involves a death or serious injury as described in § 803.3 of this chapter , or an adverse experience as described in § 314.80(a) of this chapter or § 600.80(a) of this chapter , associated with the use of the combination product, you must provide the information to the other constituent part applicant(s) for the combination product no later than 5 calendar days of your receipt of the information.

(b) With regard to information you must provide to the other constituent part applicant(s) for the combination product, you must maintain records that include:

(1) A copy of the information you provided,

(2) The date the information was received by you,

(3) The date the information was provided to the other constituent part applicant(s), and

(4) The name and address of the other constituent part applicant(s) to whom you provided the information.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

FDA guidance that cites § 4.103

Amendment history

Federal Register documents that created or amended this section.